With the advent of next-generation sequencing, an increasing number of novel gene fusions and other abnormalities have emerged recently in the spectrum of EWSR1-negative small blue round cell tumors (SBRCTs). In this regard, a subset of SBRCTs harboring either BCOR gene fusions (BCOR-CCNB3, BCOR-MAML3), BCOR internal tandem duplications (ITD), or YWHAE-NUTM2B share a transcriptional signature including high BCOR mRNA expression, as well as similar histologic features. Furthermore, other tumors such as clear cell sarcoma of kidney (CCSK) and primitive myxoid mesenchymal tumor of infancy also demonstrate BCOR ITDs and high BCOR gene expression. The molecular diagnosis of these various BCOR genetic alterations requires an elaborate methodology including custom BAC fluorescence in situ hybridization (FISH) probes and reverse transcription polymerase chain reaction assays. As these tumors show high level of BCOR overexpression regardless of the genetic mechanism involved, either conventional gene fusion or ITD, we sought to investigate the performance of an anti-BCOR monoclonal antibody clone C-10 (sc-514576) as an immunohistochemical marker for sarcomas with BCOR gene abnormalities. Thus we assessed the BCOR expression in a pathologically and genetically well-characterized cohort of 25 SBRCTs, spanning various BCOR-related fusions and ITDs and YWHAE-NUTM2B fusion. In addition, we included related pathologic entities such as 8 CCSKs and other sarcomas with BCOR gene fusions. As a control group we included 20 SBRCTs with various (non-BCOR) genetic abnormalities, 10 fusion-negative SBRCTs, 74 synovial sarcomas, 29 rhabdomyosarcomas, and other sarcoma types. In addition, we evaluated the same study group for SATB2 immunoreactivity, as these tumors also showed SATB2 mRNA upregulation. All SBRCTs with BCOR-MAML3 and BCOR-CCNB3 fusions, as well as most with BCOR ITD (93%), and all CCSKs showed strong and diffuse nuclear BCOR immunoreactivity. Furthermore, all SBRCTs with YWHAE-NUTM2B also were positive. SATB2 stain was also positive in tumors with YWHAE-NUTM2B, BCOR-MAML3, BCOR ITD (75%), BCOR-CCNB3 (71%), and a subset of CCSKs (33%). In conclusion, BCOR immunohistochemical stain is a highly sensitive marker for SBRCTs and CCSKs with BCOR abnormalities and YWHAE-rearrangements and can be used as a useful diagnostic marker in these various molecular subsets. SATB2 immunoreactivity is also present in the majority of this group of tumors.
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Key Words: small blue round cell tumor, clear cell sarcoma kidney, synovial sarcoma, BCOR, SATB2, YWHAE, immunohistochemistry (Am J Surg Pathol 2016;40:1670-1678) R ound cell sarcomas encompass a heterogenous group of tumors, which, despite similar cytomorphology of primitive small blue round cells, have diverse genetic abnormalities, clinical presentations, and outcomes. Until recently, a substantial subset of tumors resembling Ewing sarcoma microscopically and occurring in children or young adults remained unclassified, lacking known gene fusions involving EWSR1, FUS, SS18, FOXO1, etc. As a result of the wide application of next-generation sequencing to undifferentiated round cell sarcomas, an increasing number of novel genetic abnormalities have been identified including: CIC-DUX4, CIC-FOXO4, BCOR-CCNB3, BCOR-MAML3, ZC3H7B-BCOR, YWHAE-NUTM2B gene fusions or BCOR internal tandem duplication (ITD). [1] [2] [3] [4] [5] [6] However, the diagnosis of these emerging entities relies largely on elaborate molecular tests, such as fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (PCR), or genomic PCR, which are not widely available. Although the use of immunohistochemical markers remains a more practical approach to screen and support the diagnosis in this setting, there are only a handful of antibodies available that can be reliably used in the differential diagnosis of Ewing sarcoma-like tumors. Two such examples include the consistent nuclear expression of WT1 in CIC-DUX4-positive small blue round cell tumors (SBRCTs) 7 and the CCNB3 nuclear overexpression in BCOR-CCNB3positive tumors. 4, 8, 9 Although most SBRCTs harboring either BCOR genetic abnormalities or YWHAE fusions show significant BCOR mRNA upregulation, 6 no BCOR immunohistochemical marker has been investigated to date in this molecular subset of tumors. BCOR protein expression has been demonstrated by immunoblotting and immunohistochemistry in a small number of CCSKs. 10, 11 On the basis of our previous findings of BCOR and SATB2 upregulation in round cell sarcomas with BCOR ITD, YWHAE-NUTM2B, and BCOR-MAML3 fusions by RNA sequencing, 6 we sought to investigate the sensitivity and specificity of BCOR and SATB2 antibodies in this well-defined molecular cohort.
MATERIALS AND METHODS

Case Selection
Round cell sarcomas with BCOR ITD (n = 14; 8 undifferentiated round cell sarcoma, 6 primitive myxoid mesenchymal tumor of infancy [PMMTI]), YWHAE-NUTM2B (n = 2), BCOR-CCNB3 (n = 8), and BCOR-MAML3 (n = 1) gene fusions were collected from the consultation archives of the corresponding author (C.R.A.), most being previously reported. 5, 6 All 16 tumors with BCOR ITD or YWHAE-NUTM2B occurred in infants (age: 10 d to 11 mo old) and involved abdominopelvic cavity/retroperitoneum (n = 6), trunk (n = 7), and head and neck (n = 3). Among the 8 BCOR-CCNB3 tumors, 5 arose in bone (2 pelvis, 2 femur, 1 tibia) and 3 in the soft tissues (2 paraspinal, 1 chest wall), with an age range of 10 to 21 years. The BCOR-MAML3 tumor occurred as a bulky intra-abdominal mass in a 44-year-old male patient. In addition, we investigated 8 CCSKs, 4 harboring BCOR ITD and 1 YWHAE-NUTM2B/E fusion. The remaining 3 CCSKs lacking both genetic abnormalities showed typical histomorphology and age at presentation (10 mo, 19 mo, and 5 y, respectively). Three other tumors harboring ZC3H7B-BCOR fusion were tested, including 2 endometrial stromal sarcomas and 1 ossifying fibromyxoid tumor. Within the control group, there were 8 Ewing sarcomas with EWSR1-FLI1 fusion, 1 Ewing sarcoma-like with EWSR1-NFATC2 fusion, 6 SBRCTs with CIC gene rearrangements, 5 desmoplastic small round cell tumors with EWSR1-WT1 fusion, 10 SBRCTs lacking known genetic abnormalities, and 3 poorly differentiated synovial sarcomas with SS18 gene fusions. All of the above cases were tested using whole-tissue sections from formalin-fixed paraffin-embedded tissues.
To further investigate the specificity of the BCOR antibody, we screened a large spectrum of soft tissue tumors, using tissue microarrays (TMA) of synovial sarcoma (n = 71), rhabdomyosarcoma (n = 29), angiosarcoma (n = 41), low-grade fibromyxoid sarcoma (n = 14), chondrosarcoma (n = 41), and myxofibrosarcoma (n = 92). The fusion transcript types were known in a subset of synovial sarcomas, including 18 SS18-SSX1 and 16 SS18-SSX2 fusion cases.
Immunohistochemical BCOR Protein Expression Analysis
Immunohistochemical staining for BCOR was performed in all cases. A commercially available antibody, clone C-10 (sc-514576; Santa Cruz, Dallas, TX), was used for the immunohistochemical analysis. The antibody was generated against the N-terminus (1-300 amino acid) of BCOR. All assays were performed on a Leica Bond-3 autostainer platform (Leica, Buffalo Grove, IL). C-10 worked best at a dilution of 1:150 (1.7 mg/mL), using heatbased antigen retrieval, with a high pH buffer solution (Leica, ER2, 30 min) and a primary incubation time of 30 minutes. A polymer-based secondary system (Refine, Leica) was used to detect the primary reagent. A carrierbased multitissue block comprising a variety of normal tissues (spleen, placenta, kidney, colon, liver, skin, pancreas, testis, and lung) as well as molecularly pretyped tumor tissue sections were used during the antibody optimization stage and as controls. 12 Spermatogonia in the seminiferous tubules were found to show distinct nuclear stain in a clean background ( Fig. 1 ). Other normal tissues were used as negative controls.
The results were evaluated on the basis of the intensity (strong, moderate, weak, and negative) and the estimated percentage of positive tumor cells. Only nuclear stain was counted. Tumors with moderate to strong staining intensity in >10% of the tumor were considered positive.
Immunohistochemical SATB2 Protein Expression Analysis
SATB2 immunoreactivity was evaluated in a subset of cases using whole sections, including round cell sarcomas with BCOR ITD (n = 12), YWHAE-NUTM2B (n = 2), BCOR-MAML3 (n = 1), BCOR-CCNB3 (n = 7), CCSKs (n = 6), and poorly differentiated synovial sarcomas (n = 2). In addition, we tested this antibody on TMA sections of synovial sarcoma (n = 73) and rhabdomyosarcoma (n = 29). Monoclonal rabbit antibody clone EP281 (1:200; CellMarque, CA) was used for the detection of SATB2. As with C-10, the staining was performed on Leica (Bond-3) automated staining system (Leica), using heat-based antigen retrieval (ER2, Leica, 30 min) and a polymer (Leica, Refine) detection system (Leica). Normal colonic mucosa served as a positive control throughout. Only nuclear stain was considered positive. The results were recorded as described above.
Gene Expression Array and Transcription Factor Motif Analysis
To investigate the mechanism of BCOR upregulation in round cell sarcomas with BCOR abnormalities or YWHAE fusions, we analyzed the overexpressed transcription factors (TFs) in these tumors for potential binding sites to the BCOR gene promoter area (3 kb upstream from the transcription start site). Among the 404 differentially expressed gene signatures of BCOR ITD tumors by RNA sequencing, 6 there were 64 genes labeled as TF or TF-related genes, which were then searched for known motif sequences using available TF motifs databases (HOCOMOCO, motifDB, and factorbook tools).
Owing to unexpected BCOR immunoreactivity in a subset of synovial sarcomas, we further analyzed the gene expression profiles of synovial sarcoma from publicly available array data and compared them with the signature of BCOR-CCNB3 sarcomas and Ewing sarcomas, available on the same platform. Data sets from 34 synovial sarcomas (GSE20196), 10 BCOR-CCNB3 sarcomas (GSE34800), and 4 Ewing sarcomas (GSE34800) on Affymetrix Human Genome U133A Plus 2 were obtained. 4, 13 The data analysis of the 34 synovial sarcomas was also investigated in relationship to the histologic subtype (monophasic, biphasic, and poorly differentiated) according to the information provided. 13 For comparison, we included the expression data of normal human tissues and nonsarcomatous tumoral tissues (randomly selected samples from GSE16515, 14 GSE50161, 15 GSE7307). After the signal intensities were log2-transformed, the expression levels of BCOR and SATB2 in these samples were evaluated and compared with the round cell sarcomas with BCOR abnormalities or YWHAE fusions and CCSKs. The statistical t test and false discovery rate were applied to identify differentially expressed genes in synovial sarcomas comparing with the control group, using a threshold of log2 fold change negative 5 or positive 2 with 0.01 false discovery rate. A similar approach was then used to identify possible TFs leading to high BCOR expression in synovial sarcomas. In addition, as both SSX1 (Xp11.23) or SSX2 (Xp11. 22) and BCOR (Xp11.4) are located on the p-arm of chromosome X, we investigated the expression of neighboring genes within a 21.8 Mb region (chr X: 31,000,000-52,792,617) for potential coupled upregulation.
RESULTS
Strong and Diffuse BCOR Immunoexpression Across All Sarcomas With BCOR-genetic Abnormalities
The results of BCOR immunohistochemical stains are summarized in Table 1 . All SBRCTs with BCOR ITD, YWHAE-NUTM2B, BCOR-MAML3, and BCOR-CCNB3 fusions showed nuclear expression of BCOR ( Fig. 2) , except for 1 BCOR ITD-positive tumor. The staining patterns were typically strong and diffuse, except for 2 cases in the BCOR ITD group showing moderate intensity and patchy staining (60% in an abdominal wall mass of a 9-mo-old girl and 30% in a cauterized specimen from a paravertebral mass of a 10-mo-old boy). Regardless of the cytomorphologic features (round, stellate, or spindle cells), the staining pattern was diffuse. Rich capillary network and occasional fibrous septa in these tumors were distinctively negative, serving as internal negative controls. The only BCOR ITD SBRCT negative for BCOR immunohistochemical stain occurred in an 11month-old boy with a thoracic mass. The presence of BCOR ITD was reconfirmed by PCR using genomic DNA from formalin-fixed paraffin-embedded tissues, but no material was available for mRNA expression analysis.
Ewing sarcomas and CIC-rearranged tumors were negative, with only 1 case in each group showing patchy moderate nuclear positivity ( Supplementary Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/PAS/ A393). Desmoplastic small round cell tumors were also negative. Interestingly, among the 10 undifferentiated round cell sarcomas lacking known gene fusions, 2 cases were diffusely and strongly immunopositive for BCOR ( Supplementary Fig. 2 , Supplemental Digital Content 2, http://links.lww.com/PAS/A394). One of them occurred in a 1-year-old girl presenting with an orbital mass, which was negative for all immunostains tested including CD99, desmin, myogenin, TdT, CD45, etc. Morphologically, it showed diffuse sheets of monomorphic small blue round cells in a vascular-rich background. It was negative for EWSR1, FUS, CIC, YWHAE, BCOR, and SS18 gene abnormalities by FISH as well as for BCOR ITD by PCR. The other case was a 16-year-old male patient with a retroperitoneal mass and liver metastasis. Histologically, it showed a round cell sarcoma with focal spindling and focal stromal hyalinization. It was negative for EWSR1, FUS, CIC, YWHAE, BCOR, and SS18 gene rearrangements by FISH.
All 8 CCSKs showed moderate to strong BCOR immunoreactivity ( Fig. 2N) , regardless of the genetic alterations, including BCOR ITD, YWHAE fusion, or wild type for both. Cellular fibrous septa and capillaries were negative. Adjacent normal renal parenchyma was also negative.
A Subset of Synovial Sarcoma Shows BCOR Immunoreactivity
We evaluated 71 synovial sarcomas on TMA and 3 additional poorly differentiated synovial sarcomas, which could mimic other round cell sarcomas, on whole-tissue sections. Overall, 49% of synovial sarcomas had moderate to strong BCOR positivity in >10% of the tumor (Fig. 3 ). All 3 poorly differentiated synovial sarcomas had diffuse and strong BCOR staining (Fig. 3C) , whereas the 71 cases on TMA showed variable BCOR staining, ranging from negative (n = 39), moderate (n = 16), to strong (n = 16) staining. A subset of synovial sarcomas had available information regarding the histologic subtypes as monophasic or biphasic, the fusion variants as SS18-SSX1 or SS18-SSX2 and patient sexes. The immunoreactivity did not correlate with any of these factors ( Table 1 ). In biphasic synovial sarcomas, the staining was noted in both the epithelial and spindle cell components (Figs. 3B, D) . To investigate whether the BCOR protein overexpression noted in half of the synovial sarcomas is related to transcriptional upregulation, we analyzed the expression array data from the published synovial sarcoma dataset and found high BCOR mRNA levels across monophasic, biphasic, and poorly differentiated subtypes, similar to other tumors harboring BCOR gene alterations ( Fig. 4 ).
BCOR Is Not Expressed in Most Other Sarcoma Types
Most other sarcoma types tested were negative for BCOR, with only 2 of 29 rhabdomyosarcomas (1 alveolar, 1 embryonal) and 1 of 92 myxofibrosarcomas showing moderate BCOR staining. No staining was found in any of the chondrosarcomas, low-grade fibromyxoid sarcomas, and angiosarcomas TMAs. Furthermore, no BCOR reactivity was noted in the 3 cases harboring ZC3H7B-BCOR fusion (2 endometrial stromal sarcoma and 1 ossifying fibromyxoid tumor).
SATB2 Overexpression in Sarcomas With BCOR Gene Abnormalities
SATB2 immunoexpression was assessed in the same study group on the basis of the significant SATB2 mRNA upregulation in the BCOR-ITD genomic group and the availability of a commercial antibody against SATB2. SATB2 positivity was present in the majority of round cell sarcomas harboring BCOR ITD (75%), YWHAE-NUTM2B (100%), BCOR-MAML3 (100%), and BCOR-CCNB3 (71%) ( Fig. 2 and Table 1 ). However, compared with the BCOR staining pattern, SATB2 showed increased intratumoral heterogeneity in the intensity of staining. CCSK also showed variable SATB2 immunohistochemical expression. Two of 6 CCSKs tested were positive (1 BCOR ITD and 1 YWHAE fusion), with intratumoral heterogeneity being observed.
SATB2 Immunostaining Is Inconsistent in Synovial Sarcoma
As BCOR immunoreactivity was present in synovial sarcomas and rare rhabdomyosarcomas, we also evaluated SATB2 expression in these 2 additional cohorts. The results showed that only a minority of synovial sarcoma (n = 9, 12%) expressed SATB2 immunohistochemically. However, both of the poorly differentiated synovial sarcomas with 
Gene Signature and Potential TFs Regulating BCOR Expression in Tumors With BCOR Genetic Abnormalities and Synovial Sarcoma
As reported previously, we have obtained the gene signature of round cell sarcomas/PMMTI with BCOR ITD and YWHAE-NUTM2B by RNA sequencing, 6 of CCSKs by Illumina HumanHT-12 V4.0 beadchip, 16 and of BCOR-CCNB3 tumors by Affymetrix Human Genome U133A Plus 2 platform. 4 Forty-four genes, including BCOR and SATB2, were similarly upregulated in all of them. In this study, we also investigated overexpressed TFs for potential roles in transcriptional upregulation of BCOR. Thus we searched the TF motif databases for known motif sequences of differentially expressed TFs in the BCOR ITD tumors, which could target the BCOR promoter region. We identified 19 TFs, each with 1 or more possible motifs in the BCOR promoter region, including ELF2, HES7, ETV5, YWHAZ, INSM1, SOX9 (Supplementary Table 1 , Supplemental Digital Content 3, http://links.lww.com/PAS/ A395; Supplementary Figure 3 , Supplemental Digital Content 4, http://links.lww.com/PAS/A396).
We have performed a similar analysis in synovial sarcoma. Among the 411 differentially expressed genes on U133A plus 2, BCOR was significantly upregulated in all synovial sarcoma subtypes (monophasic, biphasic, and poorly differentiated) ( Fig. 4) , which correlated with the high level of immunohistochemical expression. In keeping with the inconsistent SATB2 immunoreactivity, SATB2 mRNA expression was not upregulated in synovial sarcoma as noted in other BCOR-positive tumors (Fig. 4) . Among the 70 upregulated TF or TF-associated genes, GTF2I, MYC, MSX2, and GATA6 were found to have potential binding motifs to the BCOR promoter region (Supplementary table 1, Supplemental Digital Content 3, http:// links.lww.com/PAS/A395, Supplementary Figure 3 , Supplemental Digital Content 4, Supplemental Digital Content 4, http://links.lww.com/PAS/A396). Interestingly, GATA6 was upregulated in both synovial sarcoma and BCOR-CCNB3 tumors. Moreover, GTF2I, MSX2, and GATA6 also had binding motif sequences on the promoter region of TLE1 gene, another transcriptional corepressor upregulated in synovial sarcoma. The GATA6 motifs on TLE1 and BCOR promoters were similar, whereas the motifs for GTF2I and MSX2 were different. Although there were 12 other differentially expressed TFs in common between synovial sarcomas and BCOR ITD tumors, none of them had known motifs on BCOR promoter (Supplementary table 1, Supplemental Digital Content 3, http://links.lww.com/PAS/A395). Furthermore, there were no shared patterns of mRNA expression noted in the neighboring genomic region encompassing SSX1/2 and BCOR genes to suggest a common region of amplification/upregulation.
DISCUSSION
BCOR (BCL-6 interacting corepressor) is a transcriptional corepressor involved in suppressing gene expression by either interacting with BCL-6 or binding to PCGF1 (polycomb-group RING finger homologue 1), as part of a variant Polycomb Repressive Complex 1 (PRC1), and inducing gene silencing by histone modification. 17, 18 BCOR mRNA is ubiquitously expressed in various tissues 17 ; however, the BCOR protein expression in adult human tissue is largely unknown. During our antibody validation, BCOR immunoreactivity was identified mainly in the testis, but not in other human tissues tested (spleen, placenta, kidney, colon, liver, skin, pancreas, and lung).
We have recently reported a subset of soft tissue round cell sarcomas in infants harboring BCOR ITD or YWHAE-NUTM2B fusion, occurring with predilection in the trunk and abdominal cavity. 6 Remarkably, these tumors share similar genetic abnormalities and histologic features with CCSK. 6, 19 Histologically, these lesions are characterized by uniform round cells with fine chromatin pattern and rich vascular background. Additional findings seen in a subset of cases include stellate, vacuolated, or spindle cell cytomorphology, myxoid stromal change, cellular fibrous septa, and rosette formation. Moreover, tumors previously designated as PMMTI were also shown to harbor BCOR-ITD and exhibit overlapping morphology and clinical presentation. 6 An additional molecular subset of SBRCT emerging recently is characterized by BCOR-related fusions, either by an intrachromosomal X inversion, BCOR-CCNB3, or by an interchromosomal translocation, BCOR-MAML3. 4,5 These tumors share morphologic features with BCOR-ITD SBRCTs, including monomorphic cells with delicate chromatin and indistinct nucleoli, areas of spindling, and rich capillary network. 6 Moreover, our previous study showed an overlapping gene signature between these different SBRCT subsets harboring BCOR gene abnormalities. Specifically, we noted significant upregulation of BCOR and SATB2 mRNA expression in round cell sarcomas with BCOR alterations (ITD, BCOR-CCNB3, BCOR-MAML3) and YWHAE-NUTM2B fusion, as well as in CCSKs. 6 As the molecular investigation of each of this subset requires individual custom BAC probes for FISH or primer design for PCR assays, which are not widely available for routine diagnostic use, we assessed the specificity and sensitivity of BCOR and SATB2 antibodies for immunohistochemistry in this setting. Our results showed that the overwhelming majority of SBRCTs harboring BCOR-ITD, BCOR-CCNB3, BCOR-MAML3, and YWHAE-NUTM2B abnormalities demonstrate strong and diffuse nuclear immunoreactivity to BCOR. Our study also revealed strong BCOR immunostaining in CCSKs harboring BCOR ITD, YWHAE-NUTM2B fusion, or wild-type CCSKs. . BCOR and SATB2 transcriptional upregulation is a consistent feature of SBRCT with BCOR gene abnormalities. By RNA sequencing, SBRCTs with BCOR ITD, YWHAE-NUTM2B, and BCOR-MAML3 showed BCOR mRNA upregulation compared with other SBRCT and other sarcomas (A). 6 Using different publicly available data sets, BCOR mRNA expression is also upregulated in BCOR-CCNB3 tumors as well as in all synovial sarcomas histologic subtypes (PDSS, poorly differentiated; MSS, monophasic; BSS, biphasic) by Affymetrix Human Genome U133A Plus 2 platform, as compared with Ewing sarcoma (EWSR1-FLI1) and other nonsarcomatous tumors and normal tissues (other) (B). 4, [13] [14] [15] By Illumina HumanHT-12 V4.0 beadchip, CCSK with BCOR ITD and YWHAE-NUTM2B fusion also showed high BCOR mRNA compared with normal kidney tissues. 16 In contrast, SATB2 mRNA upregulation was seen in all SBRCTs with BCOR genetic abnormalities and CCSK, but not in synovial sarcomas (D-F).
In addition to BCOR, round cell sarcomas with BCOR-CCNB3 fusion were also shown to have CCNB3 mRNA upregulation. As a consequence, CCNB3 overexpression by immunohistochemistry was demonstrated to be a useful ancillary marker in this subset. 4 No CCNB3 mRNA upregulation was identified in round cell sarcomas with BCOR ITD, BCOR-MAML3, or YWHAE-NUTM2B by RNA sequencing (data not shown); thus CCNB3 protein is most likely not overexpressed in these tumors.
Intriguingly, 2 of our undifferentiated round cell sarcomas without known gene fusions showed diffuse and strong BCOR positivity. The presence of BCOR and YWHAE rearrangements were excluded by FISH, and BCOR ITD was excluded by PCR in one of them, which occurred in an infant. This finding indicated the existence of alternative genetic events in soft tissue round cell sarcomas that can drive the tumorigenesis with high BCOR expression.
As SBRCTs with BCOR genetic abnormalities can show focal areas of spindling, the differential diagnosis often includes poorly differentiated or monophasic synovial sarcoma. Thus our investigation of BCOR immunoreactivity included a large number of synovial sarcomas, spanning all histologic subtypes and fusion transcripts. Somewhat unexpectedly, our results revealed that half of synovial sarcomas had variable degree of BCOR immunoreactivity. In contrast to the diffuse and strong staining pattern seen in SBRCTs with BCOR-gene alterations, BCOR immunoreactivity in synovial sarcomas was more variable in intensity and extent. There was no correlation between the BCOR staining pattern and histologic subtype or transcript variant of synovial sarcomas. Although all 3 poorly differentiated synovial sarcomas examined in whole sections showed diffuse and strong BCOR staining, further studies with larger case numbers are needed to determine whether the frequency of BCOR expression in poorly differentiated synovial sarcomas is different from monophasic and biphasic variants. At gene expression level, there was no significant difference in BCOR mRNA among the 3 different histologic subtypes of synovial sarcomas. It is intriguing to speculate that the histologic overlap with mixed round and spindle cell phenotype and BCOR immunoreactivity seen in both synovial sarcoma and SBRCT with BCOR-gene alterations might be related to the BCOR gene upregulation through different pathogenetic mechanisms.
In translocation-related mesenchymal tumors, BCOR gene has been involved both as 5 0 (BCOR-CCNB3 and BCOR-MAML3 in SBRCT) and 3 0 partners (ZC3H7B-BCOR in endometrial stromal sarcoma, ossifying fibromyxoid tumor, and SBRCT). 5, 20, 21 Our results showed that only tumors harboring fusions with 5 0 BCOR partner had BCOR protein overexpression by immunohistochemistry, whereas tumors with 3 0 BCOR fusions did not. All 3 tumors harboring ZC3H7B-BCOR fusion (2 endometrial stromal sarcomas and 1 ossifying fibromyxoid tumor) were negative for BCOR immunostaining. One explanation is that the BCOR monoclonal antibody sc-514576(C-10) used is against the first 300 amino acids of BCOR protein, which is not represented in the chimeric protein of ZC3H7B-BCOR. Furthermore, in contrast to the BCOR-CCNB3-positive or BCOR-MAML3-positive SBRCTs, our RNA sequencing data showed that tumors with ZC3H7B-BCOR fusion had low levels of BCOR mRNA expression.
Our study also attempted to establish the relevance of BCOR protein expression in the context of round cell sarcomas/SBRCT, as well as in the broader spectrum of different sarcoma types. In contrast to the diffuse and consistent staining results in SBRCTs with BCOR-gene abnormalities, BCOR reactivity was present with patchy moderate intensity only in 1 of the 8 Ewing sarcomas tested. Similarly, only 2/29 rhabdomyosarcomas and 1/6 round cell sarcomas with CIC rearrangements showed BCOR immunoreactivity with moderate intensity. Our results suggest that BCOR immunostaining can be used as a reliable marker in the differential diagnosis of various molecular subsets of SBRCTs, triage for further molecular studies if needed and avoid extensive immunohistochemical and molecular workups, especially in limited specimens. Aside from SBRCTs, BCOR expression was not found in other sarcomas examined, including angiosarcomas, chondrosarcomas, low-grade fibromyxoid sarcomas, endometrial stroma sarcomas, and ossifying fibromyxoid tumor with ZC3H7B-BCOR, except for 1 myxofibrosarcoma (1%) showing moderate staining.
In search of possible mechanisms of BCOR upregulation, we identified 4 differentially expressed TFs (GTF2I, MYC, MSX2, and GATA6) in synovial sarcomas that have binding motifs to the promoter region of BCOR. However, whether these TFs are involved in BCOR upregulation requires further experimental work. In contrast, SBRCTs with BCOR ITD showed 19 differentially expressed TFs with motif sequences potentially binding to the BCOR promoter; however, none overlapped with the TFs found in synovial sarcoma. Other mechanisms of BCOR overexpression may involve epigenetic regulations. The SS18-SSX fusion transcript in synovial sarcoma is involved in chromatin modification through interaction with polycomb and SWI/SNF complexes. 22, 23 For BCOR ITD tumors, the duplicated BCOR sequences reside in the region encoding the PUFD (PCGF ubiquitin-like fold discriminator) domain of BCOR, which is responsible for the binding with PCGF1 (polycomb group ring finger 1) and the formation of a variant PRC1, involved in histone modification. 6, 18, 24, 25 Another marker evaluated in this study, SATB2 (special AT-rich sequence-binding protein 2), is known as an osteoblastic as well as colorectal or appendiceal differentiation marker. [26] [27] [28] SATB2 encodes a DNA-binding protein that also interacts with chromatin remodeling molecules, such as histone deacetylase 1 and metastasisassociated protein 2. 29 Overall, SATB2 was positive in the majority (11/14; 79%) of round cell sarcomas with BCOR anomaly or YWHAE fusion. However, a greater degree of intratumoral heterogeneity with variations in the extent and intensity of staining was observed. Hence, SATB2 stain should be used with caution, especially in limited biopsy specimens. Of note, among the SATB2-positive round cell sarcomas, BCOR-CCNB3 tumors often arise as bone tumors in adolescent patients. 4 SATB2 immunoreactivity, when interpreted as an osteoblastic marker, could lead to the misdiagnosis of a small cell osteosarcoma, as seen in one of our cases. Unlike BCOR stain, SATB2 expression was only seen in 2 of 6 CCSKs tested. However, the gene expression data of CCSK revealed upregulated SATB2 expression in the majority of cases irrespective of the genotype being BCOR ITD or YWHAE fusion. This result may reflect the greater variability of SATB2 protein expression identified by immunohistochemistry. Synovial sarcoma infrequently showed SATB2 immunoreactivity, which correlated to the low levels of SATB2 mRNA expression.
In conclusion, we demonstrated BCOR immunohistochemistry as a highly sensitive marker in identifying round cell sarcomas with BCOR abnormality, namely BCOR gene rearrangement or ITD, and YWHAE fusion. CCSK shares with these soft tissue tumors not only the histomorphology, genetic changes, but also BCOR immunoreactivity. Synovial sarcoma should also be included in the differential diagnosis in round cell sarcomas positive for BCOR stain. SATB2 immunoreactivity is also expressed in the majority of these tumors, although with lower sensitivity and greater variation of staining.
